A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Public ClinicalTrials.gov record NCT07221474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.
Study identification
- NCT ID
- NCT07221474
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- Intismeran Autogene Biological
- Pembrolizumab Biological
- Carboplatin Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Placebo Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2025
- Primary completion
- Jul 1, 2029
- Completion
- May 5, 2031
- Last update posted
- Aug 20, 2026
2025 – 2031
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moffitt Cancer Center ( Site 0021) | Tampa | Florida | 33612 | Recruiting |
| VA Ann Arbor Healthcare System ( Site 0019) | Ann Arbor | Michigan | 48105 | Recruiting |
| Washington University School of Medicine ( Site 0024) | St Louis | Missouri | 63110 | Recruiting |
| Valley Health Systems - Ridgewood Campus ( Site 0010) | Paramus | New Jersey | 07652 | Recruiting |
| New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001) | Albany | New York | 12206 | Recruiting |
| Cleveland Clinic - Ohio ( Site 0016) | Cleveland | Ohio | 44195 | Recruiting |
| Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025) | Corvallis | Oregon | 97330 | Recruiting |
| Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Central/South Texas ( Site 8002) | Austin | Texas | 78745 | Recruiting |
| Virginia Cancer Specialists ( Site 0003) | Fairfax | Virginia | 22031 | Recruiting |
| Swedish Medical Center-Swedish Cancer Institute ( Site 0023) | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07221474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07221474 live on ClinicalTrials.gov.